Shift in Stem Cell Grant Policy

On Thursday, the California Institute for Regenerative Medicine is expected to approve a funding grant for a type of clinical trial that the agency has rarely made — a late-stage, Phase III clinical trial. “It’s new,” said Kevin McCormack, the senior …

[Read the full article here]

Comments are closed.